The prevalence of obesity among US adults is ~40% and is predicted to reach almost 50% by 2030. Considering the wide range of complications associated with obesity (eg, hypertension, dyslipidemia, gall bladder disease, heart disease, stroke, liver disease, type 2 diabetes, osteoarthritis, sleep apnea, respiratory problems, and many cancers), management of this chronic disease is vital. However, it is apparent that diagnosis and management of patients with obesity is suboptimal. Obesity is underdiagnosed because it is not viewed as a treatment target, and HCPs have suboptimal knowledge of current screening guidelines and best methods to implement screening measures with patients who may be reluctant to discuss weight issues. Indeed, HCPs may communicate poorly with patients regarding weight loss and evidence-based obesity treatments, including anti-obesity medications (AOMs). HCPs only rarely incorporate AOMs in management plans, indicating a failure to adhere to treatment guidelines that recommend the use of pharmacotherapy for patients who have not met weight loss goals (≥5% of total body weight at 3-6 months) with lifestyle intervention alone. In addition, when considering the growing number of pharmacologic treatment options, HCPs need to be aware of the AOMs currently approved, as well as those in late-stage clinical development, and how these might aid patients with obesity succeed in a weight loss program. Knowledge of the different agents, efficacy and safety profiles, administration characteristics, and mechanisms of action will allow clinicians to provide appropriate patient-centered care incorporating pharmacologic therapies along with the lifestyle and behavioral interventions that are the cornerstones of weight loss management.